Methods for diagnosing progressive liver fibrosis or liver cirrhosis
A non-invasive diagnostic method using sVCAM and TSP-2 with age-adjusted scoring improves diagnostic accuracy and monitoring of liver fibrosis and cirrhosis, addressing age-related performance issues and cost concerns.
Patent Information
- Application Number
- KR1020267030942
- Authority / Receiving Office
- KR · KR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-26
- Filing Date
- 2025-03-25
- Publication Date
- 2026-11-10
AI Technical Summary
Current non-invasive diagnostic methods for liver fibrosis and cirrhosis lack optimal diagnostic accuracy, are costly, and are not universally applicable across different age groups, posing risks and limitations in routine clinical practice.
A non-invasive diagnostic method using circulating levels of soluble vascular cell adhesion molecule-1 (sVCAM) and thrombospondin 2 (TSP-2) combined with subject age in a mathematical function to assign scores for diagnosing and monitoring liver fibrosis and cirrhosis, providing consistent high clinical performance across age groups.
The method offers improved diagnostic accuracy and monitoring capabilities for advanced liver fibrosis and cirrhosis, reducing age-related variability and costs, while being repeatable and risk-free.
Smart Images

Figure PCT00021_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a method for diagnosing progressive liver fibrosis or cirrhosis, predicting the prognosis or monitoring the progression of liver fibrosis in a subject, or evaluating the efficacy of an antifibrotic agent. The present invention also relates to a compound for use in the treatment of liver fibrosis, wherein the subject to be treated is identified according to the method of the present invention. Background Technology
[0002] Hepatic fibrosis, which is common in liver damage and liver disease, can have many etiologies, including, whether chronic or not, viral hepatitis B and C (HBV and HCV), co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), drug-induced liver injury (DILI), cholestatic liver disease including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), autoimmune hepatitis AIH, biliary atresia, acute liver disease (ALD), acute liver failure (ALF), cirrhosis, acute exacerbation of chronic liver failure (ACLF), Wilson's disease, metabolic disorder-associated fatty liver disease (MAFLD), metabolic disorder-associated steatohepatitis (MASH), alcohol-associated liver disease (ARLD), alcoholic liver disease, and hemochromatosis.
[0003] Liver problems can be caused by various factors that damage the liver, such as viruses, immune system abnormalities, inherited abnormal genes, cancer, alcohol use, and obesity. Over time, conditions damaging the liver can lead to scarring (cirrhosis), which can result in liver failure, a life-threatening condition requiring urgent medical care. Liver failure occurs when a large portion of the liver is damaged beyond repair.
[0004] Hepatic fibrosis is an abnormal wound repair process characterized by the excessive accumulation of extracellular matrix proteins. It is stimulated by chronic inflammation and occurs as a result of the liver's healing process when the liver becomes scarred.
[0005] Predicting liver fibrosis is a key step in the evaluation and management of patients with liver injury and / or liver disease. Therefore, since early and precise assessment of the severity and status of liver fibrosis is essential for diagnosis, monitoring, and prognosis, quantitative measurements are important for evaluating disease progression.
[0006] Most forms of liver disease are asymptomatic until the disease progresses to a late stage. Therefore, early detection is difficult. As the stage of fibrosis increases, the risk of liver-related death increases exponentially, and when cirrhosis develops, mortality and morbidity increase exponentially. Cirrhosis is the point at which the liver becomes completely scarred, exceeding its self-healing capacity.
[0007] Cirrhosis is a major cause of death and morbidity worldwide. In 2016, it was the 11th leading cause of death and the 15th leading cause of morbidity, accounting for 2.2% of global deaths and 1.5% of disability-adjusted life years. Chronic liver disease caused 1.32 million deaths worldwide in 2017 (Sepanlou, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020;5:245-266.). Cirrhosis is referred to as compensatory when there are no visible symptoms of the disease in the patient, and as decompensated when the disease has progressed to the point where the liver struggles to function and symptoms of the disease appear. Although the clinical features of decompensated cirrhosis are well described (i.e., ascites, spider nevus, jaundice, and signs of hepatic encephalopathy), patients with compensated cirrhosis often have no clinical signs and may be completely asymptomatic.
[0008] Hepatologists and healthcare providers have proposed scoring systems for staging liver fibrosis, such as the BRUNT / KLEINER system, where:
[0009] F0 refers to subjects without liver fibrosis;
[0010] F1 refers to subjects with portal vein or peritulonephropathy;
[0011] F2 refers to subjects with portal / periaportal and periacartilaginous fibrosis;
[0012] F3 refers to subjects with septal or bridging hepatic fibrosis;
[0013] F4 refers to subjects with liver cirrhosis.
[0014] Since severe liver disease (fibrosis stage F>2) can progress to hepatocellular carcinoma, accurate staging of liver fibrosis in such diseases, particularly early diagnosis of advanced liver fibrosis (fibrosis stage F3 or F4) and cirrhosis (fibrosis stage F4), is important.
[0015] Furthermore, the rate of fibrosis progression changes over time, and diagnostic tests must be performed multiple times. Therefore, this test must be risk-free for the patient, repeatable, reliable, and accurate. Consequently, non-invasive testing is required for the diagnosis of progressive liver fibrosis (F3 or F4) and cirrhosis (F4). Additionally, it is important to specifically identify patients with cirrhosis (F=4) among those with severe liver disease, as these F4 patients require emergency treatment.
[0016] To date, invasive liver biopsy remains the gold standard for evaluating liver fibrosis.
[0017] Nevertheless, liver biopsy has several recognized limitations, including sampling error, inter-observer variability, and hospitalization. A major disadvantage is the significant risk of complications, including bleeding, pain, and even death. Furthermore, since biopsy does not reflect changes throughout the liver and does not distinguish early cirrhosis from advanced cirrhosis, it does not constitute a reliable prognostic predictor (Sumida Y et al. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease / nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20: 475-485).
[0018] To avoid the life-threatening risks and diagnostic weaknesses described in detail above, using biomarkers, scores, and physical methods In vitroNon-invasive diagnostic methods have been developed. In contrast to biopsies, which cannot be repeated without discomfort, these methods allow for repeatable measurements, enabling the capture of the dynamic processes of fibrosis resulting from progression and regression. These methods are based on readily available biochemical data and clinical features, such as the FIB4 test (Sterling RK et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV / HCV coinfection. Hepatology 2006; 43:1317-1325), or tests that directly measure markers of fibrosis and fibrolysis, such as the Enhanced Liver Fibrosis (ELF) test (Guha, IN, et al., Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-460).
[0019] However, replacing liver biopsy with these methods remains controversial and is not generally accepted due to insufficient diagnostic performance. The main problem with these two biochemical tests is that they cannot reliably distinguish advanced stages of liver fibrosis in individual patients. Additionally, the ELF test is expensive, which constitutes a disadvantage when the test is repeated. Furthermore, FIB4 performs poorly in patients under 35 years of age and has lower specificity in patients over 65 years of age.
[0020] Physical methods include imaging based on high-frequency sound waves (ultrasound and echocardiography), computed tomography (CT), magnetic resonance imaging (MRI), transient elastography (TE, FibroScan), as well as scintillation. The major disadvantages of physical measurements are high cost, low availability of equipment, and complexity of the methods, which limit routine clinical practice.
[0021] In addition, obesity, ascites, acute inflammation, hepatic congestion, and elevated portal pressure can reduce the accuracy of ultrasound TE (Fibroscan) by, for example, affecting the velocity of the shear wave. Furthermore, falsely increased liver stiffness due to increased postprandial portal pressure was observed in this method.
[0022] Therefore, there remains an unmet medical need to develop new non-invasive diagnostic methods that offer optimal diagnostic accuracy compared to biopsy and are also useful for monitoring the time course of liver fibrosis and / or demonstrating response to given drugs. Furthermore, it is important to provide new methods that offer the best predictability with the lowest cost and easiest feasibility. means of solving the problem
[0023] Summary of the Invention
[0024] The inventors performed highly precise and complete multiple analyses on a cohort of 3,875 patients at different stages of fibrosis to provide a novel and highly sensitive non-invasive diagnostic and monitoring method for advanced liver fibrosis (F3 or F4) and liver cirrhosis (F4). WO 2024 / 013229 describes a method for non-invasively diagnosing these diseases by measuring the circulating levels of two biomarkers: soluble vascular cell adhesion molecule-1 (sVCAM) and thrombospondin 2 (TSP-2). This method demonstrates accurate diagnosis of advanced liver fibrosis and liver cirrhosis compared to liver biopsy and existing solutions. However, the inventors recently observed that the diagnostic performance of this method may not be homogeneous across different age subgroups. To investigate this issue, the inventors successfully developed a new mathematical function capable of correcting for the influence of age on diagnostic performance by combining the circulating levels of these biological markers measured in biological fluid samples isolated from subjects with the age of the subjects in a mathematical function. This mathematical function provides improved diagnosis of progressive liver fibrosis (F3 or F4) and liver cirrhosis (F4) compared to existing solutions. Most importantly, compared to methods combining only the levels of sVCAM and TSP-2, the method of the present invention provides consistent high clinical performance independent of the patient's age, which enables reliable monitoring of liver fibrosis.
[0025] Accordingly, the first aspect of the present invention is for diagnosing progressive liver fibrosis (F3 or F4) or liver cirrhosis (F4) in a subject. In vitro It relates to a method, and the above method includes the following:
[0026] a) (i) circulating levels of soluble vascular cell adhesion molecule-1 (sVCAM) and thrombospondin 2 (TSP-2) in a biological fluid sample separated from the subject, and (ii) the age of the subject;
[0027] b) A step of assigning a score by combining the levels and ages of the provided sVCAM and TSP-2 in a mathematical function;
[0028] c) A step of diagnosing or predicting the prognosis of progressive liver fibrosis or liver cirrhosis in the subject by comparing the above score with a cutoff value.
[0029] In a specific implementation, the score is the score SA obtained through the following mathematical function:
[0030]
[0031] Here
[0032] y = β0 + β1*log 10 (TSP2 (ng / mL)) + β2*log 10 (sVCAM (ng / mL)) + β3 *(Age (years) 3 )
[0033] Here:
[0034] β0 is between -40 and -14, and specifically between -38 and -17;
[0035] β1 is between 1.7 and 6.7, and specifically between 2.2 and 6.3;
[0036] β2 is between 3.0 and 12, and specifically between 3.5 and 11.5;
[0037] β3 is -6 e -06 and 2.5 e -6 It is between, and especially -5 e -6 and 2 e -6 It is between.
[0038] In a more specific embodiment, a score SA higher than the cutoff value co1 indicates progressive liver fibrosis, specifically co1 is between 0.2 and 0.7, and more specifically co1 is between 0.25 and 0.63.
[0039] In another specific embodiment, a score SA higher than the cutoff value CO2 indicates liver cirrhosis, specifically CO2 is between 0.4 and 0.9, and more specifically CO2 is between 0.5 and 0.85.
[0040] Another aspect of the present invention is for monitoring the progression of liver fibrosis in a subject. In vitro This relates to a method, and the above method includes the following steps:
[0041] a) (i) the circulation levels of sVCAM and TSP-2 in a biological fluid sample separated from the subject, and (ii) the age of the subject;
[0042] b) a step of assigning a score SC by combining the levels and ages of the provided sVCAM and TSP-2 in a mathematical function; and
[0043] c) a step of comparing the score SC with the score SB obtained by combining the levels of sVCAM and TSP-2 and age previously measured in the same subject using the same mathematical function.
[0044] In a specific embodiment, an increase in SC relative to SB indicates progression of liver fibrosis. In another specific embodiment, a decrease in SC relative to SB indicates regression of liver fibrosis. In a specific embodiment, the absence of a significant change between SC and SB measured over a certain period of time in the same subject indicates that liver fibrosis is stable.
[0045] In a specific embodiment of the above method, step (a) of the method for monitoring the progression of liver fibrosis is performed at least 3 months after a previous measurement of the levels of sVCAM and TSP-, particularly during a period between 3 months and 10 years after a previous measurement of the levels of sVCAM and TSP-2, more particularly during a period between 3 months and 2 years.
[0046] In a specific embodiment of the above method, one event associated with a change in pathological condition occurs between SB and SC during monitoring. In a specific embodiment, the event is selected from liver transplantation, acute exacerbation of chronic liver fibrosis, compensated cirrhosis, decompensated cirrhosis, development of ascites, and the presence of esophageal varices on endoscopy.
[0047] In a preferred embodiment, the SB and SC are calculated through the mathematical function defined above.
[0048] A third aspect of the present invention relates to a method for evaluating the efficacy of an antifibrotic agent in the treatment of progressive liver fibrosis or liver cirrhosis, said method comprising:
[0049] a) (i) circulating levels of sVCAM and TSP-2 in a biological fluid sample isolated from a subject suffering from progressive liver fibrosis, wherein the subject was administered an antifibrotic agent prior to the isolation of the biological fluid sample, and (ii) the age of the subject;
[0050] b) a step of assigning a score SE by combining the levels and ages of the provided sVCAM and TSP-2 in a mathematical function; and
[0051] c) A step of comparing the score SE with the score SD obtained by combining the levels of sVCAM and TSP-2 and age previously measured before administering the antifibrotic agent to the same subject using the same mathematical function.
[0052] In particular, a decrease in SE relative to SD indicates the efficacy of the antifibrotic agent; an increase in SE relative to SD indicates the inefficacy of the antifibrotic agent and / or the patient's non-responsiveness.
[0053] In a preferred embodiment, the SE and SD are calculated through the mathematical function defined above.
[0054] In a preferred embodiment, the biological fluid sample of the subject used in the method of the present invention is interstitial fluid, saliva, urine, or whole blood sample. In a specific embodiment, the biological fluid sample of the subject used in the method of the present invention is a blood sample, plasma sample, or serum sample. Preferably, the biological fluid sample is acellular. More preferably, the blood sample is a serum sample from the subject.
[0055] Another aspect of the present invention relates to a method for predicting the prognosis of changes in liver fibrosis in a subject having biopsy-proven stage 1, 2, or 3 liver fibrosis, said method comprising:
[0056] a) (i) the circulation levels of sVCAM and TSP-2 in a biological fluid sample of the subject, and (ii) the age of the subject;
[0057] b) a step of assigning a score SF by combining the levels and ages of the provided sVCAM and TSP-2 in a mathematical function; and
[0058] c) A step of predicting the prognosis of changes in liver fibrosis in the subject by comparing the above score with a cutoff value.
[0059] In a specific embodiment, an SF score higher than the cutoff value indicates that the subject's liver fibrosis will progress (i.e., the subject will become a liver fibrosis worsener); an SF score lower than the cutoff value indicates that the subject's liver fibrosis will regress (i.e., the subject will become a liver fibrosis improver); and an SF score that is neither higher nor lower than the cutoff value indicates that the subject's liver fibrosis will stabilize.
[0060] Another aspect of the present invention also provides an antifibrotic agent for use in the treatment of progressive liver fibrosis or cirrhosis in a subject, said subject diagnosed with progressive liver fibrosis or cirrhosis according to the method of the present invention, said agent is selected from the group consisting of pegbelpermin, cenicriviroc, dapagliflozin, dulaglutide, empagliflozin, fenofibrate, ranifibranor, liraglutide, obeticholic acid, pioglitazone, resmetirom, saroglitazar magnesium, seladelfar, semaglutide, sitagliptin, TERN-101, TERN-201, tropexor, ambrisentan, BMS-963272, BMS-986251, BMS-986263, HepaStem, LYS006, MET409, MET642 and orlistat.
[0061] In a specific embodiment, the formulation is Resmetirom. Brief explanation of the drawing
[0062] Figure 1A shows the mean scores of the modeling ST for patients under 50 years of age (0) and over 60 years of age (1) in a homogenized subgroup (n=339 patients per category). ****: p < 0.0001. Figure 1B shows the mean scores of modeling ST II for patients under 50 years of age (0) and over 60 years of age (1) in homogenized subgroups (n=339 patients per category). "ns": No significant difference between the scores obtained from the two patient groups. Figure 2A shows the clinical performance of the modeling ST for the detection of F3. "Spe": Specificity; "Sen": Sensitivity. Figure 2B shows the clinical performance of the modeling ST II for the detection of F3. "Spe": Specificity; "Sen": Sensitivity. Figure 3 shows the ROC curves for the detection of progressive liver fibrosis using modeling ST II and other conventional non-invasive tests (FIB-4, ELF, NFS, and APRI) in a validation cohort of 1,850 subjects. Figure 4 shows the ROC curves for the detection of liver cirrhosis using modeling ST II and other conventional non-invasive tests (FIB-4, ELF, NFS, and APRI) in a validation cohort of 1,850 subjects. Figure 5 shows a box plot of SF scores calculated at the screening visit (V0) for the "Improving," "Stable," and "Deteriorating" categories of patients with liver fibrosis proven by biopsy at stage 1, 2, or 3 in V0. Improving: Patients with a lower fibrosis stage at Visit 7 (after 81 weeks) compared to V0; Stable: Patients with the same fibrosis stage at Visit 7 compared to V0; Deteriorating: Patients with a higher fibrosis stage at Visit 7 compared to V0. The line above the box plot represents the pairwise p-values (Student test) of the box plot values. Specific details for implementing the invention
[0063] definition
[0064] Fibrosis scoring / staging
[0065] According to the present invention, the term "fibrosis" or "hepatic fibrosis" refers to a pathological condition in which fibrous connective tissue is excessively deposited in the liver. More specifically, fibrosis is a pathological process involving the continuous formation of fibrous scars and the overproduction of extracellular matrix by connective tissue as a response to tissue damage. Physiologically, the deposition of connective tissue can lead to the loss of structure and function of the liver.
[0066] Different stages of liver fibrosis are defined by the Kleiner scoring system (Kleiner et al, Hepatology 2005, Vol 41, Issue 6, 1313-1321), where:
[0067] F0 refers to subjects without liver fibrosis;
[0068] F1 refers to subjects with portal vein or peritulonephropathy;
[0069] F2 refers to subjects with portal / periaportal and periacartilaginous fibrosis;
[0070] F3 refers to subjects with septal or bridging hepatic fibrosis;
[0071] F4 refers to subjects with liver cirrhosis.
[0072] Stages F0-2 are assigned to subjects with early liver fibrosis, F3 or F4 are assigned to subjects with advanced liver fibrosis, and stage F4 is assigned to subjects with liver cirrhosis.
[0073] Using this fibrosis staging system, patients with no or minimal fibrosis (F=0 or 1) are generally not considered to be at risk of liver cirrhosis, liver failure, HCC (hepatocellular carcinoma), or liver-related death. Patients with severe (F>2) liver fibrosis are at risk of developing liver cirrhosis, liver failure, HCC, and liver-related death. Patients with compensated liver cirrhosis (F=4) are at high risk of liver failure (uncompensated liver cirrhosis), HCC, and liver-related death.
[0074] In the context of the present invention, the term "progressive fibrosis" or "progressive hepatic fibrosis" refers to a fibrosis stage of F≥3, i.e., fibrosis stage F3 or fibrosis stage F4.
[0075] In the context of the present invention, the term "cirrhosis" or "hepatic cirrhosis" refers to the fibrosis stage of F4.
[0076] The terms "subject" and "patient" may be used interchangeably herein and refer to human subjects.
[0077] In the context of the present invention, the terms "biomarker," "marker," and "biological marker" are interchangeable.
[0078] Within the scope of the present invention, any range shall be deemed to include an upper limit and a lower limit.
[0079] Simultaneous non-invasive examination
[0080] Fibrosis-4 (FIB-4) index is age (years) x AST (U / L) / platelets (x 10 9 It is calculated as / L) / √ALT(U / L), where AST is aspartate aminotransferase and ALT is alanine aminotransferase.
[0081] The Enhanced Liver Fibrosis Panel (ELF, Siemens Healthcare GmbH, Eriangen, Germany) is a test that predicts fibrosis based on three fibrosis biomarkers: hyaluronic acid (HA), stromal metalloproteinase-1 tissue inhibitor (TIMP-1), and amino-terminal propeptide of procollagen type III (PIIINP). This test uses the following formula to calculate the ELF score (2.278 + 0.851 ln(C HA ) + 0.751 ln(C PIIINP ) + 0.394 ln(C TIMP-1 Calculate )), where C is the concentration of the biomarker.
[0082] The NFS score is calculated as follows: NFS = - 1.675 + 0.037 x Age (years) + 0.094 x BMI (kg / m²) 2 ) + 1.13 * IGF / Diabetes (Yes = 1, No = 0) + 0.99 x AST / ALT ratio - 0.013 x Platelets (× 10 9 / l) - 0.66 x Albumin (g / dl)
[0083] The APRI score is calculated as follows:
[0084] APRI=[(AST level (IU / L) / Upper limit of normal AST range (IU / L)) X 100] / Platelet count(× 10 9 / L).
[0085] Diagnostic performance analysis
[0086] Sensitivity is the ability of a test to accurately identify individuals with the disease. Sensitivity measures the proportion of positive ("disease") cases in a population of patients assessed using a standard method ("gold standard"), or the most reliable proportion possible when considering biopsy profiling. Sensitivity (Se) is the proportion of positive results (true positives = TP) divided by the total number of patients with the disease (TP + false negatives = FN): Se = TP / (TP + FN). Sensitivity is typically expressed as a percentage (%) ranging from 0 to 100%.
[0087] A true positive (TP) subject is a subject with a disease in which the value of the parameter of interest is higher than the cutoff.
[0088] False negative (FN) subjects are subjects with a disease in which the value of the parameter of interest is lower than the cutoff.
[0089] Specificity is the ability of a test to accurately identify individuals without disease. Specificity measures the proportion of negative ("healthy") cases in a population of healthy patients evaluated using the standard method ("gold standard"). Specificity (Sp) is the proportion of negative results (true negatives = TN) divided by the total number of healthy patients (TN + false positives = FP): Sp = TN / (TN + FP).
[0090] A true negative (TN) subject is a disease-free subject whose value of the parameter of interest is lower than the cutoff.
[0091] False positive (FP) subjects are disease-free subjects whose value of the parameter of interest is higher than the cutoff.
[0092] The prevalence of a given group is the number of disease cases within the group.
[0093] The positive predictive value (PPV) is the probability of having the disease when the test is positive. PPV = Number of true positives / (Number of true positives + Number of false positives). PPV = TP / (TP + FP).
[0094] The Net Present Value (NPV) is the probability of not having the disease when the test is negative. NPV = Number of True Negatives / (Number of True Negatives + Number of False Negatives). NPV = TN / (TN + FN).
[0095] Prevalence affects PPV and NPV differently. As the prevalence of the disease increases in a population, PPV increases while NPV decreases. While changes in PPV are more significant, NPV is somewhat less affected by disease prevalence. For low prevalence (5–10%), PPV values are low. At the same time, NPV is high. For high prevalence (80–90%), PPV values are high, while the opposite is true for NPV.
[0096] The likelihood ratio is defined as the ratio of the expected test result in subjects with a specific condition or disease to the test result in subjects without the disease.
[0097] The likelihood ratio for a positive test result (LR+) represents the ratio of the probability of a positive test result occurring in subjects with the disease compared to subjects without the disease. LR+ = Sensitivity / (1-Specificity). LR+ is the best indicator for confirming a diagnosis. The higher the LR+, the more the test indicates the disease. LR+ > 5 indicates a moderate to significant increase in evidence of the presence of the disease. A good diagnostic test has an LR+ > 10, and its positive result contributes significantly to the diagnosis.
[0098] The likelihood ratio for a negative test result (LR-) represents the ratio of the probability of a negative result occurring in a subject with the disease to the probability of the same result occurring in a subject without the disease. LR- = (1 - Sensitivity) / Specificity. LR- is a good indicator for diagnostic exclusion. An LR- between 0.1 and 0.2 indicates a moderate probability of accurately diagnosing a patient without the studied condition. A good diagnostic test for a patient without the studied condition has an LR- < 0.1.
[0099] For each individual cutoff, there is a pair of diagnostic sensitivity and specificity values. To construct a Receiver Operational Characteristic (ROC) graph, these pairs of values are plotted on the graph with 1-specificity on the x-axis and sensitivity on the y-axis. The shape of the ROC curve and the Area Under the Receiver Operational Characteristic (AUROC) indicate how high the discriminative power of the test is. The closer the curve is to the upper-left corner and the larger the area under the curve, the better the test distinguishes between subjects with and without the disease. The area under the curve can have any value between 0.5 and 1 and is a good indicator of the test's excellence. A complete diagnostic test has an AUROC of 1.0, while a non-discriminating test has an AUROC of 0.5. AUROC is an overall measure of diagnostic accuracy.
[0100] The "average score" is the average of the test results calculated in the group.
[0101] Method of the present invention
[0102] As mentioned above, progressive liver fibrosis and cirrhosis are associated with liver-related mortality, and therefore, the easy detection of subjects with progressive fibrosis and cirrhosis is of paramount importance. The present invention provides a solution to these unmet needs.
[0103] In the method of the present invention, the levels of two circulating markers measured in a biological fluid sample separated from a subject and the age of the subject are combined in a mathematical function to assign a score. The circulating markers are as follows: soluble vascular cell adhesion molecule-1 (sVCAM) and thrombospondin 2 (TSP-2). sVCAM is also known as VCAM 1, INCAM-100, CD106 and is registered in the UniProt database under number P19320. TSP-2 is also known as THBS2 and is registered in the UniProt database under number P35442.
[0104] According to the present invention, the circulating levels of sVCAM and TSP-2 are measured in a biological fluid sample of a subject. In all methods and embodiments presented herein, the biological fluid sample may be a sample of blood or blood-derived fluid, such as serum and plasma, saliva, interstitial fluid, or urine. In a specific embodiment, the biological fluid sample of the subject is a blood, serum, or plasma sample. In a more specific embodiment, the sample is a serum sample. In yet another specific embodiment, the biological fluid sample is a cell-free sample.
[0105] According to the present invention, biological fluid samples can be analyzed immediately after collection or stored in a low-temperature environment, for example, a freezer, for further analysis.
[0106] The circulating levels of sVCAM and TSP-2 can be measured by any conventional methodology well known in the art, such as immunoassays (e.g., ELISA (enzyme-linked immunosorbent assay), immunoturbidimetry, immunonephlometry, immunocytometry, protein arrays). For example, the levels of sVCAM and TSP-2 can be determined by antibodies, aptamers, or peptides targeting the respective markers.
[0107] In some methods of the present invention, circulating levels of sVCAM and TSP-2 are measured in multiple blood-derived samples separated from a subject at the same or different time points over a period of months to years. In this case, the same type of sample is used whenever a measurement is to be performed. For clarity, this means that if a previous measurement was performed in a serum sample, a subsequent measurement is performed in a serum sample from the same subject. Likewise, if a previous measurement was performed in a blood or plasma sample, a subsequent measurement is performed in a blood or plasma sample from the same subject, respectively.
[0108] According to the method of the present invention, the levels of two biomarkers measured in a biological fluid sample separated from a subject and the age of the subject are combined in a mathematical function to assign a score. For clarity, the age of the subject to be used in the mathematical function is the age at the time the biological fluid sample was separated from the subject to measure the levels of the two biomarkers.
[0109] The above score correlates with the subject's fibrotic status. The score can be used for the diagnosis or prognosis prediction of progressive liver fibrosis or cirrhosis in the subject. Furthermore, the score correlates with changes in liver fibrosis, which enables not only diagnosis but also the monitoring of liver fibrosis progression or the evaluation of the efficacy of antifibrotic agents in the treatment of progressive liver fibrosis or cirrhosis.
[0110] In the context of the present invention, those skilled in the art know a number of suitable methods for developing mathematical functions, all of which are within the scope of the present invention. In a specific embodiment, the mathematical function includes a logistic regression equation.
[0111] In an additional implementation example, the score is assigned by the following mathematical function:
[0112]
[0113] Here
[0114] y = β0 + β1*log 10 (TSP2 (ng / mL)) + β2*log 10 (sVCAM (ng / mL)) + β3 *(Age (years) 3 )
[0115] Here:
[0116] β0 is between -40 and -14, and specifically between -38 and -17;
[0117] β1 is between 1.7 and 6.7, and specifically between 2.2 and 6.3;
[0118] β2 is between 3.0 and 12, and specifically between 3.5 and 11.5;
[0119] β3 is -6 e -06 and 2.5 e -6 It is between, and especially -5 e -6 and 2 e -6 It is between.
[0120] In a specific embodiment, the present invention is for diagnosing or predicting the prognosis of progressive liver fibrosis or liver cirrhosis in a subject. In vitro It relates to a method, and the above method includes the following:
[0121] a) (i) the circulation levels of sVCAM and TSP-2 in a biological fluid sample separated from the subject, and (ii) the age of the subject;
[0122] b) a step of assigning a score by combining the levels and ages of the provided sVCAM and TSP-2 in a mathematical function; and
[0123] c) A step of diagnosing or predicting the prognosis of progressive liver fibrosis or liver cirrhosis in the subject by comparing the above score with a cutoff value.
[0124] By comparing the obtained score with a specific cutoff value, it can be used to distinguish subjects with progressive liver fibrosis or cirrhosis from subjects without progressive liver fibrosis or cirrhosis, or to predict changes in the subject's liver fibrosis.
[0125] According to a specific embodiment, the present invention is for diagnosing progressive liver fibrosis or liver cirrhosis in a subject. In vitro This concerns the method, where the score is SA, which is obtained through the mathematical function defined above.
[0126] According to an embodiment of the present invention, the SA value is compared with a cutoff value (co). The value can be calculated from the Youden statistical analysis of SA scores obtained from a training group. The "training group" refers to a group consisting of a given number of subjects, wherein the fibrosis stage of each subject is already determined by a method of the prior art, such as a liver biopsy.
[0127] In particular, the above SA and cutoff values are calculated using a mathematical function to distinguish patients with progressive liver fibrosis from patients without progressive liver fibrosis.
[0128] Alternatively, the above SA and cutoff values are calculated using a mathematical function to distinguish patients with liver cirrhosis from patients without liver cirrhosis.
[0129] A cutoff value CO1 can be determined to be used to indicate the presence or absence of progressive liver fibrosis. A cutoff value CO2 can be determined to be used to indicate the presence or absence of liver cirrhosis.
[0130] In a more specific embodiment, the present invention is for diagnosing progressive liver fibrosis in a human subject. In vitro It relates to a method, and the above method includes the following:
[0131] a) (i) the circulation levels of sVCAM and TSP-2 in a biological fluid sample separated from the subject, and (ii) the age of the subject,
[0132] b) A step of calculating the score SA based on step (a) using a mathematical function,
[0133] c) A step of comparing this SA with the cutoff value co1,
[0134] d) Here, SA greater than the cutoff value co1 indicates subjects with progressive liver fibrosis.
[0135] In contrast, a calculated SA value lower than the cutoff value co1 indicates a subject without progressive liver fibrosis.
[0136] In another more specific embodiment, the present invention is for diagnosing liver cirrhosis in a human subject. In vitro This relates to a method, and the above method includes the following.
[0137] a) (i) the circulation levels of sVCAM and TSP-2 in a biological fluid sample separated from the subject, and (ii) the age of the subject,
[0138] b) A step of calculating the score SA based on step (a) using a mathematical function,
[0139] c) A step of comparing this SA with the cutoff value CO2,
[0140] d) Here, SA greater than the cutoff value CO2 indicates a subject with liver cirrhosis.
[0141] In contrast, a calculated SA value lower than the cutoff value CO2 indicates a subject without liver cirrhosis.
[0142] In a specific embodiment, the score A (SA), cutoff value co1, and cutoff value co2 used for the diagnosis of progressive liver fibrosis or cirrhosis are calculated according to the mathematical function defined above for the training group.
[0143] In a specific embodiment, SA is compared to a cutoff value co1 indicating progressive liver fibrosis. In particular, co1 is between 0.2 and 0.7, more particularly between 0.25 and 0.63, and particularly equal to 0.3358.
[0144] In another specific embodiment, SA is compared to a cutoff value CO2 indicating liver cirrhosis. Specifically, CO2 is between 0.4 and 0.9, more specifically between 0.5 and 0.85, and particularly equal to 0.5829.
[0145] According to another aspect, the present invention relates to a computer program comprising instructions that, when executed by a processor / processing means, cause the processor / processing means to perform the following:
[0146] - Receiving the levels of sVCAM and TSP-2 measured in biological fluid samples isolated from the subject and the age of the subject;
[0147] - Calculating SA with these measured levels and ages from a mathematical function as described herein; and
[0148] - Assigning subjects to the group of subjects with progressive liver fibrosis or cirrhosis based on a comparison of the calculated score with a predetermined cutoff value.
[0149] The present invention also provides a computer-readable medium comprising a computer program described therein. According to a specific embodiment, the computer-readable medium is a non-transient medium or a storage medium.
[0150] The present invention also relates to predicting the prognosis of changes in liver fibrosis in subjects with biopsy-proven stage 1, 2, or 3 liver fibrosis. In vitro This relates to a method, and the above method includes the following.
[0151] a) (i) the circulation levels of sVCAM and TSP-2 in a biological fluid sample of the subject, and (ii) the age of the subject;
[0152] b) a step of assigning a score SF by combining the levels and ages of the provided sVCAM and TSP-2 in a mathematical function; and
[0153] c) A step of predicting the prognosis of changes in liver fibrosis in the subject by comparing the above score with a cutoff value.
[0154] According to this embodiment, a subject's score SF higher than the cutoff value indicates that the subject's liver fibrosis will progress; a subject's score SF lower than the cutoff value indicates that the subject's liver fibrosis will regress; and a subject's SF score that is neither higher nor lower than the cutoff value indicates that the subject's liver fibrosis will stabilize.
[0155] The cutoff value to be used in this method varies depending on the stage of liver fibrosis of the subject. According to this embodiment, the SF score of a subject with biopsy-proven stage 1 liver fibrosis is compared with the cutoff value CO-F1; the SF score of a subject with biopsy-proven stage 2 liver fibrosis is compared with the cutoff value CO-F2; and the SF score of a subject with biopsy-proven stage 3 liver fibrosis is compared with the cutoff value CO-F3.
[0156] Cutoff values CO-F1, CO-F2, and CO-F3 can be determined in a training group with biopsy-proven stable stage 1, 2, or 3 liver fibrosis, respectively. For example, the cutoff value CO-F1 is determined in a training group with biopsy-proven stable stage 1 liver fibrosis. If the patient's liver fibrosis stage does not change after the screening visit and 18 months after the screening visit, the patient is considered to have stable liver fibrosis. For example, if the liver fibrosis stage of a patient with biopsy-proven stage 1 liver fibrosis remains at stage 1 even after 18 months after the screening visit, the patient is considered to have stable liver fibrosis.
[0157] According to an embodiment, the cutoff value of the SF score may be a range of values. According to a specific embodiment, the cutoff value CO-F1 is a range consisting of 0.09 and 0.27; the cutoff value CO-F2 is a range consisting of 0.29 and 0.45; and the cutoff value CO-F3 is a range consisting of 0.45 and 0.83.
[0158] In a specific embodiment, if the SF score of a subject with biopsy-proven stage 1 liver fibrosis is higher than the range consisting of 0.09 and 0.27, it indicates that the subject's liver fibrosis will progress; if the subject's score SF is lower than the above range, it indicates that the subject's liver fibrosis will regress; and if the subject's SF score falls within the above range, it indicates that the subject's liver fibrosis will stabilize.
[0159] In another specific embodiment, if the SF score of a subject with biopsy-proven stage 2 liver fibrosis is higher than the range consisting of 0.29 and 0.45, it indicates that the subject's liver fibrosis will progress; if the subject's score SF is lower than the above range, it indicates that the subject's liver fibrosis will regress; and if the subject's SF score falls within the above range, it indicates that the subject's liver fibrosis will stabilize.
[0160] In another specific embodiment, if the SF score of a subject with biopsy-proven stage 3 liver fibrosis is higher than the range consisting of 00.45 and 0.83, it indicates that the subject's liver fibrosis will progress; if the subject's score SF is lower than the above range, it indicates that the subject's liver fibrosis will regress; and if the subject's SF score falls within the above range, it indicates that the subject's liver fibrosis will stabilize.
[0161] According to another specific embodiment, the cutoff value of the SF score may be a specific value. According to a more specific embodiment, the cutoff value CO-F1 is a value selected from a range consisting of 0.09 and 0.27; the cutoff value CO-F2 is a value selected from a range consisting of 0.29 and 0.45; and the cutoff value CO-F3 is a value selected from a range consisting of 0.45 and 0.83. More specifically, the cutoff value CO-F1 may be 0.16; the cutoff value CO-F2 may be 0.37; and the cutoff value CO-F3 may be 0.63.
[0162] In a specific embodiment, if the SF score of a subject with biopsy-proven stage 1 liver fibrosis is higher than a CO-F1 value selected from a range consisting of 0.09 and 0.27, this indicates that the subject's liver fibrosis will progress; if the subject's SF score is lower than the selected CO-F1 value, this indicates that the subject's liver fibrosis will regress; and if the subject's SF score is equal to the selected CO-F1 value, this indicates that the subject's liver fibrosis will stabilize.
[0163] In another specific embodiment, if the SF score of a subject with biopsy-proven stage 2 liver fibrosis is higher than a CO-F2 value selected from a range consisting of 0.29 and 0.45, this indicates that the subject's liver fibrosis will progress; if the subject's SF score is lower than the selected CO-F2 value, this indicates that the subject's liver fibrosis will regress; and if the subject's SF score is equal to the selected CO-F2 value, this indicates that the subject's liver fibrosis will stabilize.
[0164] In another specific embodiment, if the SF score of a subject with biopsy-proven stage 3 liver fibrosis is higher than a CO-F3 value selected from a range consisting of 0.45 and 0.83, this indicates that the subject's liver fibrosis will progress; if the subject's SF score is lower than the selected CO-F3 value, this indicates that the subject's liver fibrosis will regress; and if the subject's SF score is equal to the selected CO-F3 value, this indicates that the subject's liver fibrosis will stabilize.
[0165] The present invention also relates to a computer program comprising instructions that cause the processor / processing means to perform the following when executed by the processor / processing means:
[0166] - (i) levels of sVCAM and TSP-2 measured in biological fluid samples from subjects with biopsy-proven stage 1, 2, or 3 liver fibrosis; and (ii) receiving the age of the subject
[0167] - Calculating SF scores from these measured levels through mathematical functions;
[0168] - Comparing the SF score with a predetermined cutoff value of the SF score, and
[0169] - Assigning the object as follows:
[0170] Subjects with liver fibrosis progression when the SF score is higher than the cutoff value;
[0171] Subjects for whom liver fibrosis will regress if the SF score is lower than the cutoff value:
[0172] Subjects with stable liver fibrosis when the SF score is neither higher nor lower than the cutoff value.
[0173] The present invention also provides an in vitro method for monitoring the progression of liver fibrosis in a subject by measuring the levels of two circulating markers, namely sVCAM and TSP-2.
[0174] In particular, the above method includes the following steps:
[0175] a) (i) the circulation levels of sVCAM and TSP-2 in a biological fluid sample separated from the subject, and (ii) the age of the subject;
[0176] b) a step of assigning a score SC by combining the levels and ages of the provided sVCAM and TSP-2 in a mathematical function; and
[0177] c) a step of comparing the score SC with the score SB obtained by combining the levels of sVCAM and TSP-2 and age previously measured in the same subject using the same mathematical function.
[0178] As used herein, the term "monitoring" refers to tracking changes in a disease or pathological condition. Monitoring is the continuous and systematic collection and analysis of data as a protocol or pathological condition progresses, for example, during a clinical study or treatment protocol.
[0179] Since the SC score is calculated using a non-invasive method and correlates with changes in liver fibrosis, it enables not only diagnosis but also easy monitoring of the progression of liver fibrosis through repeated measurements.
[0180] In a specific embodiment, circulating levels of sVCAM and TSP-2 are measured in at least two blood-derived samples from a subject.
[0181] Longitudinal changes in scores can be evaluated by collecting at least two samples from the same subject over time. For example, a first score designated as SB can be calculated from the levels of sVCAM and TSP-2 previously measured in the subject's biological fluid sample and the corresponding age, and a second score designated as SC can be calculated from the levels of sVCAM and TSP-2 subsequently measured in the same subject's biological fluid sample and the corresponding age. SB and SC can be obtained through the mathematical function defined above. If the scores increase over time in the same subject—that is, SC is higher than SB—it implies that liver fibrosis is worsening, whereas if SC decreases over time in the same subject—that is, SC is lower than SB—it implies that liver fibrosis is decreasing. The absence of a significant change between SC and SB measured over a constant period in the same subject indicates that liver fibrosis is stable.
[0182] Since the score calculated according to the mathematical function defined above is a linear value, the method of the present invention can also determine the likelihood that a subject with progressive liver fibrosis will progress to liver cirrhosis or worsening liver cirrhosis by comparing score C (SC) with score B (SB). Therefore, the change in the value between SC and SB during follow-up is an indicator of liver fibrosis progression or liver fibrosis regression.
[0183] In a specific embodiment, SC is measured during the occurrence of an event associated with a change in pathological status. The event includes liver transplantation, acute exacerbation of chronic liver fibrosis (ACLF), compensated and decompensated cirrhosis, development of ascites, and the presence of esophageal varices on endoscopic examination. Preferably, the event is acute exacerbation of chronic liver fibrosis, compensated and decompensated cirrhosis.
[0184] In a specific embodiment, SC is measured at least 3 months after the measurement of SB, particularly during the period between 3 months and 10 years after the measurement of SB, preferably during the period between 3 months and 2 years, more preferably during the period between 1 year and 2 years.
[0185] In a more specific embodiment, if the subject is diagnosed with liver cirrhosis by, for example, the method of the present invention described above, the SC is measured at 3 months, preferentially at 3 months, during the period between 3 months and 2 years after the measurement of the SB. The appropriate time for the SC measurement may vary depending on the comorbidity.
[0186] Comorbidities include malignant tumors, type 2 diabetes, overweight and obesity, heart disease, and kidney disease.
[0187] In another specific embodiment, if the subject is diagnosed with progressive liver fibrosis, for example by the method of the present invention described above, SC is measured at a period between 1 and 10 years after the measurement of SB. The appropriate time point for SC measurement depends on the comorbidity.
[0188] Thanks to the method of the present invention, it is possible to decide to provide lifestyle recommendations (e.g., providing dietary therapy or physical activity recommendations) to a subject to treat progressive liver fibrosis or cirrhosis, to medically manage the subject (e.g., establishing regular visits to a doctor or regular examinations, e.g., to regularly monitor liver damage markers), or to administer at least one liver fibrosis therapy to the patient. In particular, it is possible to decide to provide lifestyle recommendations to a subject or to administer at least one liver fibrosis therapy. Accordingly, the present invention relates to an antifibrotic compound for use in a method for treating progressive liver fibrosis or cirrhosis in a subject who requires further assistance, wherein the subject is identified thanks to the method according to the present invention.
[0189] The present invention also relates to a computer program comprising instructions that cause the processor / processing means to perform the following when executed by the processor / processing means:
[0190] - Receiving the levels of sVCAM and TSP-2 measured in biological fluid samples isolated from the subject and the age of the subject;
[0191] - Calculating the score SC with these measured levels and ages from the mathematical function as described above;
[0192] - Comparing the score SC with the score SB obtained by combining the levels of sVCAM and TSP-2 and age previously measured in the same subject using the same mathematical function, and
[0193] - Assigning the object as follows:
[0194] If the SC score is higher than the SB score, it indicates progression of liver fibrosis;
[0195] If the SC score is lower than the SB score, it indicates regression of liver fibrosis; or
[0196] If there is no significant change between SC and SB, it is considered to have stable liver fibrosis.
[0197] Accordingly, the present invention relates to an antifibrotic compound for use in a method for treating progressive liver fibrosis or liver cirrhosis in a subject who additionally requires this, wherein the subject is identified thanks to the method according to the present invention.
[0198] As used herein, the term "treatment" refers to both therapeutic measures and preventive or protective measures, the objective of which is to prevent or slow (reduce) undesirable physiological changes or disorders. Beneficial or desirable clinical outcomes include, but are not limited to, the alleviation of symptoms, the stabilization of the pathological condition (specifically, without deterioration), the delay or cessation of disease progression, and the improvement or alleviation of the pathological condition. In particular, for the purposes of the present invention, treatment is aimed at slowing the progression of fibrosis and reducing the risk of additional complications. This may also entail extending survival compared to the survival expected without treatment.
[0199] Antifibrotic agents are administered at a therapeutically effective dose. As used herein, the term "therapeutically effective dose" refers to the amount of drug effective in achieving a desired therapeutic outcome. The therapeutically effective dose of a drug may vary depending on factors, such as the individual's disease state, age, sex, and weight, and the drug's ability to induce a desirable response in the individual. The therapeutically effective dose is also an amount in which the therapeutically beneficial effect outweighs any toxic or adverse effects of the agent. The effective dose and administration regimen for the drug depend on the disease or pathological condition to be treated and can be determined by a person skilled in the art. A physician with ordinary skill in the art can easily determine and prescribe the effective dose of the necessary pharmaceutical composition. For example, a physician may start the dose of the drug used in the pharmaceutical composition at a level lower than that required to achieve a desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. Generally, the appropriate dose of the composition of the present invention will be the amount of the compound that is the lowest effective dose to produce a therapeutic effect according to a specific administration regimen. This effective dose will generally vary depending on the factors described above.
[0200] The present invention further relates to an antifibrotic compound for use in a method for treating liver fibrosis in F3 or F4 patients, wherein the patient is classified as having progressive liver fibrosis or cirrhosis according to the method of the present invention. The present invention also relates to an antifibrotic compound for use in a method for treating liver fibrosis, wherein the subject diagnosed or classified as having progressive liver fibrosis or cirrhosis is treated with an antifibrotic compound defined below thanks to the method according to the present invention.
[0201] Antifibrotic compounds include the following:
[0202] - Compound of formula (I) or pharmaceutically acceptable salt thereof:
[0203]
[0204] Here:
[0205] X1 represents a halogen atom, an R1 group, or a G1-R1 group;
[0206] A represents a CH=CH or CH2-CH2 group;
[0207] X2 represents the G2-R2 group;
[0208] G1 represents an oxygen atom;
[0209] G2 represents an oxygen or sulfur atom;
[0210] R1 represents an alkyl group substituted with one or more substituents selected from a hydrogen atom, an unsubstituted alkyl group, an aryl group or a halogen atom, an alkoxy group, an alkylthio group, a cycloalkyl group, a cycloalkylthio group, and a heterocyclic group;
[0211] R2 represents an alkyl group substituted with a -COOR3 group, where R3 represents an alkyl group substituted or not substituted with one or more substituents selected from hydrogen atoms or halogen atoms, cycloalkyl groups and heterocyclic groups.
[0212] Identical or different R4 and R5 represent alkyl groups that are substituted or not substituted with one or more substituents selected from halogen atoms, cycloalkyl groups, and heterocyclic groups;
[0213] - AMP-activated protein kinase stimulants, e.g., PXL-770, MB-11055, Debio-0930B, metformin, CNX-012, O-304, mangiferin calcium salt, eltrombopac, carotuximab, and imeglimin;
[0214] - Bile acids, e.g., obeticholic acid (OCA), ursodeoxycholic acid (UDCA), norursodeoxycholic acid and ursodiol;
[0215] - CCR antagonists, e.g., cenicriviroc (CCR2 / 5 antagonist), PG-092, RAP-310, INCB-10820, RAP-103, PF-04634817, and CCX-872;
[0216] - Dipeptidyl peptidase IV (DPP4) inhibitors, e.g., evogliptin, vidagliptin, potagliptin, alogliptin, saxagliptin, tilogliptin, anagliptin, sitagliptin, retagliptin, melogliptin, sogliptin, trelagliptin, teneligliptin, dutogliptin, linagliptin, gemigliptin, yogliptin, betagliptin, imigliptin, omagliptin, vidagliptin, and denagliptin;
[0217] - Farnesoid X receptor (FXR) agonists, e.g., obeticholic acid (OCA), tropexor (LJN452), cilofexor (GS9674), nidupexor (LMB763), EDP-305, AKN-083, INT-767, GNF-5120, LY2562175, INV-33, NTX-023-1, EP-024297, Px-103, SR-45023, TERN-101 (6-{4-[5-cyclopropyl-3-(2,6-dichloro-phenyl)-isoxazole-4-ylmethoxy]-piperidine-1-yl}-1-methyl-1H-indole-3 carboxylic acid), TERN-201, TERN-501 and TERN-301;
[0218] - Fibroblast growth factor 19 (FGF-19) receptor ligand or functionally modified variant of FGF-19;
[0219] - Fibroblast growth factor 21 (FGF-21) agonists, e.g., PEG-FGF21 (Pegbelpermin, formerly BMS-986036), YH-25348, BMS-986171, YH-25723, LY-3025876, and NNC-0194-0499;
[0220] - Engineered fibroblast growth factor 19 (FGF-19) analogs, e.g., NGM-282 (aldafermin);
[0221] - Glucagon-like peptide-1 (GLP-1) analogs, e.g., semaglutide, liraglutide, exenatide, albiglutide, dulaglutide, lixisenatide, loxenatide, efpeglenatide, taspoglutide, MKC-253, DLP-205, and ORMD-0901;
[0222] - Nicotinic acid, e.g. niacin and vitamin B3;
[0223] - Nitazoxanide (NTZ), its active metabolite Tizoxanide (TZ), or other precursor drugs of TZ, e.g., RM-5061;
[0224] - PPAR alpha agonists, e.g., fenofibrate, ciprofibrate, pemafibrate, gemfibrozil, clofibrate, vinifibrate, clinofibrate, clofibric acid, nicopybrate, pyrifibrate, flafibride, ronifibrate, theofibrate, tocofibrate, and SR10171;
[0225] - PPAR gamma agonists, e.g., pioglitazone, deuterated pioglitazone, rosiglitazone, efatotazone, ATx08-001, OMS-405, CHS-131, THR-0921, SER-150-DN, KDT-501, GED-0507-34-Levo, CLC-3001 and ALL-4;
[0226] - PPAR delta agonists, e.g., GW501516 (Endurabol or ({4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-yl}methyl)sulfanyl]-2-methylphenoxy}acetic acid)), MBX8025 (Seladelpar or {2-methyl-4-[5-methyl-2-(4-trifluoromethyl-phenyl)-2H-[l,2,3]triazole-4-ylmethylsilphanyl]-phenoxy}acetic acid), GW0742 ([4-[[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methylphenoxy]acetic acid), L165041, HPP-593 and NCP-1046;
[0227] - PPAR alpha / gamma dual agonists (also named glitasar), e.g. saroglitazar, aleglitazar, muraglitazar, tesaglitazar, and DSP-8658;
[0228] - PPAR gamma / delta dual agonists, e.g., conjugated linoleic acid (CLA) and T3D-959;
[0229] - PPAR alpha / gamma / delta pan-agonists or PPARpan agonists, e.g., IVA337, TTA (tetradecylthioacetate), babakinin, GW4148, GW9135, bezafibrate, ranifibranor, lobeglitazone, and CS038;
[0230] - Sodium-glucose transporter (SGLT) 2 inhibitors, e.g., ricoglifosin, remogliflozin, dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin, ipragliflozin, tianagliflozin, canagliflozin, topogliflozin, zanagliflozin, bexagliflozin, luceogliflozin, sergliflozin, HEC-44616, AST-1935, and PLD-101.
[0231] - Stearoyl CoA desaturase-1 inhibitor / fatty acid bile acid conjugates, e.g., Aramcol, GRC-9332, Steemcol, TSN-2998, GSK-1940029, and XEN-801;
[0232] - Thyroid receptor β (THR β) agonists, e.g., VK-2809, Resmetirom (MGL-3196), MGL-3745, SKL-14763, Sovetirom, BCT-304, ZYT-1, MB-07811, and Eprothirom;
[0233] - Vitamin E and isoforms; Vitamin E combined with Vitamin C and atorvastatin.
[0234] In the present invention, the antifibrotic compound is preferably selected from the group consisting of pegbelpermin, cenicriviroc, dapagliflozin, dulaglutide, empagliflozin, fenofibrate, ranifibranor, liraglutide, obeticholic acid, pioglitazone, resmetirom, saroglitazar magnesium, seladelfar, semaglutide, sitagliptin, TERN-101, TERN-201, tropexor, ambrisentan, BMS-963272, BMS-986251, BMS-986263, HepaStem, LYS006, MET409, MET642 and orlistat (Xenical).
[0235] More preferably, the antifibrotic agent is selected from pegbelpermin, cenicriviroc, dapagliflozin, dulaglutide, empagliflozin, fenofibrate, ranifibranor, liraglutide, obeticholic acid, pioglitazone, resmetirom, saroglitazar magnesium, seladelfar, semaglutide, sitagliptin, TERN-101, TERN-201, and tropexor.
[0236] In a more specific embodiment, the antifibrotic agent is resmetirom.
[0237] The present invention further relates to a method for evaluating the efficacy of an antifibrotic agent in a subject suffering from progressive liver fibrosis or liver cirrhosis, said method comprising:
[0238] a) (i) circulating levels of sVCAM and TSP-2 in a biological fluid sample isolated from a subject suffering from progressive liver fibrosis, wherein the subject was administered an antifibrotic agent prior to the isolation of the biological fluid sample, and (ii) the age of the subject;
[0239] b) a step of assigning a score SE by combining the levels and ages of the provided sVCAM and TSP-2 in a mathematical function; and
[0240] c) A step of comparing the score SE with the score SD obtained by combining the levels of sVCAM and TSP-2 and age previously measured before administering the antifibrotic agent to the same subject using the same mathematical function.
[0241] According to the above method, the levels of sVCAM and TSP-2 are measured in a sample separated before the administration of an antifibrotic agent and a sample separated after the administration, respectively, to obtain a first score named SD (before administration) and a second score named SE (after administration).
[0242] The above SD and SE can be obtained through the same mathematical function, in particular the mathematical function defined above.
[0243] If SE is higher than SD, liver fibrosis worsens, which means the subject does not respond to treatment with antifibrotic agents or that treatment is ineffective.
[0244] If SE is lower than SD, liver fibrosis regresses, which means the subject responds to treatment using antifibrotic agents and the treatment is effective.
[0245] If SD is the same as SE, liver fibrosis is stable.
[0246] The present invention also relates to a computer program comprising instructions that cause the processor / processing means to perform the following when executed by the processor / processing means:
[0247] - (i) levels of sVCAM and TSP-2 measured in a biological fluid sample isolated from a subject suffering from progressive liver fibrosis, wherein the subject was administered an antifibrotic agent prior to the isolation of the biological fluid sample, and (ii) receiving the age of the subject;
[0248] - Calculating SE with these measured levels and ages from the mathematical function as described above;
[0249] - Comparing the score SC with the score SD obtained by combining the previously measured levels of sVCAM and TSP-2 and age in the same subject using the same mathematical function prior to the administration of an antifibrotic agent; and
[0250] - Assigning the object as follows:
[0251] Subjects who do not respond to treatment with antifibrotic agents when the SE score is higher than the SD;
[0252] Subjects who respond to treatment with antifibrotic agents when the SE score is lower than the SD; or
[0253] If there is no significant change between SE and SD, it is considered to have stable liver fibrosis.
[0254] The present invention also relates to a data processing device comprising means for carrying out one of the methods of the present invention as described above.
[0255] The present invention also provides a computer program product or a computer-readable storage medium comprising instructions that, when executed by a computer, cause the computer to perform one of the methods of the present invention as described above.
[0256] The present invention is further described with reference to the following non-limiting embodiments.
[0257] Examples
[0258] 1. Dataset
[0259] The study population was composed of patients screened for potential inclusion in the Resolve-It Phase 3 clinical trial. All patients with available biopsy results and blood samples for biomarker measurement with less than 90 days between the biopsy and blood collection dates were selected as potentially useful for this study.
[0260] · Training dataset
[0261] Patients with complete data on multiple biomarkers as well as conventional demographic and clinical parameters (age, sex, type 2 diabetes, dyslipidemia, arterial hypertension [HT], BMI) were selected to maximize both the number of patients and biomarkers. This selection yielded a total of N=1640 patients with complete data on 40 biomarkers. To control for potential confounding factors when processing the modeling and selection of related biomarkers, two propensity score matching algorithms (PSM) were applied to homogenize the following parameters: first between F<3 (F0F2) and F=4 (F4) patients, and second between the previously matched F=4 and F=3 (F3).
[0262] To balance the distribution of fibrosis stages in the training dataset, two patients from group F0F2 in the first PSM were matched with each patient from group F4. Through this process, n=272 patients were selected, namely 136 from group F0F2, 68 from group F3, and 68 from group F4, who were well balanced for the parameters listed above (Table 1). In this training cohort, the mean age of the patients was 58 years, 60% were male, and 53% had T2D (Type 2 diabetes).
[0263] · Validation dataset
[0264] For the training process, a biomarker panel including two biomarkers, namely sVCAM and TSP-2, was selected.
[0265] Based on these results, all patients who were not part of the training dataset were selected, satisfying the conditions that available measurements for these biomarkers, availability of biopsy results, and an interval between blood date and biopsy date of ≤ 90 days were present. This resulted in an independent validation dataset containing N=1850 patients. Key characteristics are reported in Table 1 below.
[0266] · Statistical analysis
[0267] Descriptive statistics for baseline characteristics were generated and reported as mean ± sd or %(n), and patients without progressive fibrosis or cirrhosis were compared with those with it using appropriate 2-sample tests (Student t-test for mean comparison and χ² test for percentage comparison).
[0268] The modeling process was performed using a stepwise algorithm that starts with an empty model and sequentially inserts variables that minimize this criterion, comparing binomial logistic regression models for the detection of progressive fibrosis or liver cirrhosis based on the associated BIC (Bayesian Information Criterion). The process was stopped when none of the remaining variables resulted in a decrease in the BIC value. The stat R package (step function) was used for this purpose. The regression coefficients of the selected models were extracted, and the associated 95% CIs were reported.
[0269] Specific cutoff values were derived using the training dataset. For the detection of F≥3, a low cutoff to achieve 85% sensitivity (Sen) and a high cutoff to achieve 90% specificity (Spe) were extracted, and the diagnostic performance (Sen, Spe, PPV, NPV, Acc) associated with these cutoffs was calculated for both the training and validation datasets. For the detection of F=4, a low cutoff to achieve 85% Sen and a high cutoff to achieve 95% Spe were extracted, and the diagnostic performance (Sen, Spe, PPV, NPV, Acc) associated with these cutoffs was calculated for both the training and validation datasets. Additionally, the Youden cutoff that maximizes Sen + Spe was reported for each endpoint.
[0270] The overall diagnostic performance of non-invasive tests and biomarkers was estimated using AUROC values, and significant differences in these statistics were tested using the Delong test. AUROC values were reported along with 95% CIs estimated using 1,000 bootstrap samples.
[0271] A box plot was presented along with the associated Student t-test for mean comparison, and the p-values were reported graphically as follows:
[0272] ****: p < 0.0001, ***: p < 0.001, **: p < 0.01, *: p < 0.05 and NS: p ≥ 0.05
[0273] All propensity score matching algorithms were executed using the matchit function from the MatchIt R package.
[0274] All statistical analyses were performed using R version 4.3.0.
[0275] Table 1: Technical characteristics of the cohort
[0276]
[0277] 2. Results
[0278] 2.1 Modeling Development
[0279] When the stepwise algorithm was executed, the combination of TSP2 and SVCAM returned the lowest BIC, so it was identified as the optimal biomarker combination, and the addition of additional biomarkers did not result in a reduction sufficient to be considered significant.
[0280] Furthermore, it is important to ensure that any diagnostic test can be interpreted independently of patient characteristics. Therefore, modeled STAs were used to analyze the effects of different potential confounding factors, namely age, sex, prevalence of type 2 diabetes (T2D), dyslipidemia, arterial hypertension (HT), body mass index (BMI), fibrosis, steatosis, ballooning degeneration, and graded lobular inflammation:
[0281]
[0282] Here
[0283] y= -30.001 + 8.64 × log10 (sVCAM (g / L)) + 5.750 × log10 (TSP-2 (ng / mL))
[0284] Through this process, two subgroups were generated for each parameter of interest (age, sex, gender, hypertension, dyslipidemia, and T2D), and each time these subgroups were well balanced with respect to the other parameters listed above. Notably, regarding age, two subgroups were generated, one including patients aged 50 and the other including patients aged 60, thereby clearly separating the ages between the two subgroups; additionally, a second PSM was performed for an extreme case study using patients aged ≤45 and patients aged ≥65. For BMI, a group of patients with a BMI of ≤29 and a second group of patients with a BMI of ≥31 were generated. A total of 1,124 patients (562 in each category), 678 patients (339 in each category), 1,048 patients (524 in each category), 1,084 patients (542 in each category), 750 patients (375 in each category), and 1,052 patients (526 in each category) were extracted for gender, age, T2D, HT, BMI, and dyslipidemia, respectively.
[0285] Among the six confounding factors, only age had a significant effect on the mean score of the modeling ST, and the score was significantly higher in patients over 60 years of age (p value <0.0001, see Fig. 1A).
[0286] A new mathematical model was developed to obtain a score that is not affected by the age of the subject.
[0287] Using a binomial logistic regression model, the following equation (named ST II) was obtained:
[0288]
[0289] Here
[0290] y = β0 + β1*log 10 (TSP2 (ng / mL)) + β2*log 10 (sVCAM (ng / mL)) + β3 *(Age (years) 3 )
[0291] The coefficients of this model were reported in Table 2 along with the associated 95% CI, all of which reached high significance with an associated p-value <0.0001.
[0292] Table 2: Summary of coefficients
[0293]
[0294] The effect of age on the mean values of scores and biomarkers, Gpe 0 (under 50 years old) and Gpe 1 (over 60 years old) is shown in Fig. 1B.
[0295] These results demonstrate that Modeling ST II exhibited consistent clinical performance regardless of the patient's age grade when compared to the mean score of Modeling ST. To illustrate this, the inventors extracted the Youden cutoff for F3 detection (0.3831 for ST and 0.3358 for ST II) from the validation dataset and calculated the clinical performance of Modeling ST and ST II. It can be observed that the specificity of Modeling ST decreased with increasing patient age, while the sensitivity increased with increasing age (Fig. 2A). This result indicates that the clinical performance of Modeling ST is not homogeneous across all age groups. Conversely, the specificity and sensitivity of Modeling ST II are homogeneous and constant across all age groups (Fig. 2B).
[0296] Based on the modeling ST II and training dataset, the following cutoff values were extracted to achieve 85% sensitivity and 90% specificity for the detection of F≥3 in Table 3 and 85% sensitivity and 95% specificity for the detection of F=4 in Table 4.
[0297] Table 3: Low (Lc, 85%Sen), Youden, and High (Hc, 90%Spe) Cutoffs for F3 Detection
[0298]
[0299] Table 4: Low (Lc, 85%Sen), Youden, and High (Hc, 95%Spe) Cutoffs for F4 Detection
[0300]
[0301] 2.2 Verification of ST II Diagnostic Performance
[0302] Next, the diagnostic performance of the modeled ST II obtained from both the training and validation datasets was calculated for both endpoints. These statistics were derived using low and high cutoffs and reported in Table 5 for detections of F≥3 and in Table 6 for detections of F=4.
[0303] Table 5: ST II Performance Verification for Detection of Progressive Fibrosis
[0304]
[0305] Table 6: ST II Performance Verification for Detection of Liver Cirrhosis
[0306]
[0307] · Detection of F≥3
[0308] In the validation cohort, at a low cutoff, the modeled ST II achieved a sensitivity of 0.85 and a specificity of 0.63, with an NPV of 0.89. Similarly, at a high cutoff, ST II achieved a specificity of 0.9 and a PPV of 0.74 combined with a sensitivity of 0.52. Interestingly, only 29% of patients fell into the Indeterminate Risk Zone (IRZ). Overall, ST II and its associated performance were validated.
[0309] · Detection of F=4
[0310] In the validation cohort, at a low cutoff, ST II achieved a sensitivity of 0.86 and a specificity of 0.76, with an NPV of 0.99. Similarly, at a high cutoff, ST II achieved a specificity of 0.9 and a PPV of 0.19 combined with a sensitivity of 0.56. Interestingly, only 15% of patients fell into the Indeterminate Risk Zone (IRZ), meaning that nearly 4 / 5 had clinically manageable test results using ST II. Overall, ST II and its associated performance were validated.
[0311] 2.3 Comparison of ST II Performance vs. Other NITs
[0312] The overall performance of ST II for the detection of F≥3 was also compared with other conventional non-invasive tests, namely FIB-4, ELF, NFS, and APRI.
[0313] The associated Delong test toc was calculated to test the AUROC values and the AUROC difference between ST II and other NITs. The results for detection of F≥3 are summarized in Table 7, and the results for detection of F=4 are summarized in Table 8.
[0314] Table 7: AUROC values for the detection of progressive fibrosis
[0315]
[0316] Table 8: AUROC values for the detection of liver cirrhosis
[0317]
[0318] The ROC curve for the detection of F≥3 is graphed in Fig. 3, and the ROC curve for the detection of F=4 is graphed in Fig. 4.
[0319] For the detection of F≥3, ST II achieved an AUROC of 0.83, which was significantly higher than that achieved by other NITs, and all p-values were <0.0001. For the detection of F=4, ST II achieved an AUROC of 0.86, which was significantly higher than that achieved by other NITs. These results confirm the high performance of the method of the present invention and, in particular, the benefits of using this new diagnostic test over conventional tests.
[0320] 2.4 Prognostic Performance of SF Score
[0321] To evaluate the prognostic performance of the method, 612 patients included in the clinical trial were used. These patients had available information and biopsy results regarding sVCAM and TSP2 at both the screening visit (V0) and Visit 7 (V7, 81 weeks later) of the clinical trial, and had biopsy-verified stage 1, 2, or 3 hepatic fibrosis at V0. The SF scores for these patients were calculated at V0. For each patient group with early stage 1, 2, or 3 fibrosis, three categories of fibrotic change were defined:
[0322] · Improved patients: Patients with a lower fibrosis stage in V7 compared to V0
[0323] · Stable: Patients with the same fibrosis stage in V7 compared to V0
[0324] · Exacerbators: Patients with a higher fibrosis stage in V7 compared to V0
[0325] There are a total of 9 patient subgroups. The number of patients in each subgroup is shown in Table 9 below.
[0326] Table 9:
[0327]
[0328] Comparison of the SF scores of each subgroup showed that a low SF score in V0 indicated that the subject's liver fibrosis would regress, while a high SF score in V0 indicated that the subject's liver fibrosis would progress (Fig. 5).
[0329] Verification of the prognostic performance of the 2.5 SF score
[0330] To verify the prognostic performance of the SF score, 27 patients with biopsy-verified stage 1, 2, or 3 liver fibrosis were classified into V0 according to the biopsy-based fibrosis stage. Blood samples were collected from these patients simultaneously. The patients' SF scores were calculated according to the method of the present invention and compared with the cutoff value ranges based on the original fibrosis stage in V0 (i.e., CO-F1: range between 0.09 and 0.27; CO-F2: range between 0.29 and 0.45; CO-F3: range between 0.45 and 0.83). After comparison, the patients were predicted to improve, remain stable, or deteriorate. The course of the disease assessed by the score was verified by biopsy in V7. The SF score of each patient and the course of the disease assessed in V7 are summarized in Table 10. The results demonstrate the performance of the SF score in predicting the prognosis of changes in liver fibrosis in subjects with biopsy-confirmed stage 1, 2, or 3 liver fibrosis.
[0331] Table 10:
[0332]
[0333]
Claims
Claim 1 To diagnose or predict the prognosis of progressive liver fibrosis or cirrhosis in subjects In vitro A method comprising: a) (i) circulating levels of soluble vascular cell adhesion molecule-1 (sVCAM) and thrombospondin 2 (TSP-2) in a biological fluid sample separated from the subject, and (ii) the age of the subject; b) assigning a score by combining the provided levels of sVCAM and TSP-2 and the age in a mathematical function; and c) diagnosing or predicting the prognosis of progressive liver fibrosis or cirrhosis in the subject by comparing the score with a cutoff value. Claim 2 In claim 1, a method wherein the score is a score SA obtained through the following mathematical function: Here, y = β0 + β1*log 10 (TSP2 (ng / mL)) + β2*log 10 (sVCAM (ng / mL)) + β3 *(Age (years) 3 Here: β0 is between -40 and -14, particularly between -38 and -17; β1 is between 1.7 and 6.7, particularly between 2.2 and 6.3; β2 is between 3.0 and 12, particularly between 3.5 and 11.5; and β3 is -6 e -06 and 2.5 e -6 It is between, and especially -5 e -6 and 2 e -6 It is between. Claim 3 A method according to claim 1 or 2, wherein a score SA higher than the cutoff value co1 indicates progressive liver fibrosis, particularly co1 is between 0.2 and 0.7, more particularly co1 is between 0.25 and 0.
63. Claim 4 A method according to claim 1 or 2, wherein a score SA higher than the cutoff value CO2 indicates liver cirrhosis, particularly CO2 is between 0.4 and 0.9, more particularly CO2 is between 0.5 and 0.
85. Claim 5 To monitor the progression of liver fibrosis in subjects In vitro A method comprising the following steps: a) providing (i) circulating levels of sVCAM and TSP-2 in a biological fluid sample separated from the subject, and (ii) the age of the subject; b) assigning a score SC by combining the provided levels of sVCAM and TSP-2 and the age in a mathematical function; and c) comparing the score SC with a score SB obtained by combining previously measured levels of sVCAM and TSP-2 and the age in the same subject in the same mathematical function. Claim 6 In claim 5, - an increase in SC compared to SB indicates progression of liver fibrosis; - a decrease in SC compared to SB indicates regression of liver fibrosis; and - no difference between SC and SB indicates stable liver fibrosis. Claim 7 A method according to claim 6, wherein SC is measured at least 3 months after the measurement of SB, particularly during a period between 3 months and 10 years, preferably during a period between 3 months and 2 years. Claim 8 A method according to any one of claims 5 through 7, wherein SC or SB is calculated through the following mathematical function: Here, y = β0 + β1*log 10 (TSP2 (ng / mL)) + β2*log 10 (sVCAM (ng / mL)) + β3 *(Age (years) 3 Here: β0 is between -40 and -14, particularly between -38 and -17; β1 is between 1.7 and 6.7, particularly between 2.2 and 6.3; β2 is between 3.0 and 12, particularly between 3.5 and 11.5; and β3 is -6 e -06 and 2.5 e -6 It is between, and especially -5 e -6 and 2 e -6 It is between. Claim 9 A method for evaluating the efficacy of an antifibrotic agent in treating progressive liver fibrosis or liver cirrhosis, comprising the following steps: a) providing circulating levels of sVCAM and TSP-2 in a biological fluid sample isolated from a subject suffering from progressive liver fibrosis, wherein the subject was administered an antifibrotic agent prior to the measurement, and (ii) the age of the subject; b) assigning a score SE by combining the provided levels of sVCAM and TSP-2 and the age in a mathematical function; and c) comparing the score SE with a score SD obtained by combining the levels of sVCAM and TSP-2 and the age previously measured prior to administering the antifibrotic agent to the same subject in the same mathematical function. Claim 10 In claim 9, a method in which a reduction in SE compared to SD indicates the efficacy of an antifibrotic agent. Claim 11 In claim 9 or 10, a method in which SE and SD are calculated through the following mathematical function: Here, y = β0 + β1*log 10 (TSP2 (ng / mL)) + β2*log 10 (sVCAM (ng / mL)) + β3 *(Age (years) 3 Here: β0 is between -40 and -14, particularly between -38 and -17; β1 is between 1.7 and 6.7, particularly between 2.2 and 6.3; β2 is between 3.0 and 12, particularly between 3.5 and 11.5; and β3 is -6 e -06 and 2.5 e -6 It is between, and especially -5 e -6 and 2 e -6 It is between. Claim 12 A method according to any one of claims 1 to 11, wherein the biological fluid sample is a saliva sample, interstitial fluid sample, urine sample, blood sample, plasma sample, or serum sample. Claim 13 In claim 12, the biological fluid sample is a serum sample. Claim 14 As an antifibrotic agent for use in the treatment of progressive liver fibrosis or cirrhosis in a subject, wherein the subject is diagnosed as having progressive liver fibrosis or cirrhosis according to the method of any one of claims 1 to 4, and said agent is selected from the group consisting of pegbelpermin, cenicriviroc, dapagliflozin, dulaglutide, empagliflozin, fenofibrate, ranifibranor, liraglutide, obeticholic acid, pioglitazone, resmetirom, saroglitazar magnesium, seladelfar, semaglutide, sitagliptin, TERN-101, TERN-201, tropexor, ambrisentan, BMS-963272, BMS-986251, BMS-986263, HepaStem, LYS006, MET409, MET642, and orlistat Antifibrotic agent. Claim 15 An antifibrotic agent for use in the treatment of progressive liver fibrosis or cirrhosis in a subject, wherein the subject is diagnosed as having progressive liver fibrosis or cirrhosis according to the method of any one of claims 1 to 4, and the agent is Resmetirom. Claim 16 To predict the prognosis of changes in liver fibrosis in subjects with biopsy-proven stage 1, 2, or 3 liver fibrosis In vitro A method comprising: a) (i) providing circulating levels of sVCAM and TSP-2 in a biological fluid sample of the subject, and (ii) the age of the subject; b) assigning a score SF by combining the provided levels of sVCAM and TSP-2 and the age in a mathematical function; and c) predicting the prognosis of changes in liver fibrosis in the subject by comparing the score with a cutoff value. Claim 17 In Clause 16, a method in which the score SF is obtained through the following mathematical function: Here, y = β0 + β1*log 10 (TSP2 (ng / mL)) + β2*log 10 (sVCAM (ng / mL)) + β3 *(Age (years) 3 Here: β0 is between -40 and -14, particularly between -38 and -17; β1 is between 1.7 and 6.7, particularly between 2.2 and 6.3; β2 is between 3.0 and 12, particularly between 3.5 and 11.5; and β3 is -6 e -06 and 2.5 e -6 It is between, and especially -5 e -6 and 2 e -6 It is between. Claim 18 A method according to claim 16 or 17, wherein an SF score higher than the cutoff value indicates that the subject's liver fibrosis will progress; an SF score lower than the cutoff value indicates that the subject's liver fibrosis will regress; and an SF score neither higher nor lower than the cutoff value indicates that the subject's liver fibrosis will stabilize. Claim 19 A computer assistance program comprising instructions that, when executed by a processor / processing means, cause the processor / processing means to perform the following: (i) levels of sVCAM and TSP-2 measured in a biological fluid sample separated from a subject; and (ii) receiving the age of the subject; (i) calculating an SA score from these measured levels through a mathematical function; and (i) comparing the calculated score with a predetermined cutoff value to assign the subject to a group of subjects with progressive liver fibrosis or liver cirrhosis. Claim 20 A computer program comprising instructions that, when executed by a processor / processing means, cause the processor / processing means to perform the following: - receiving the levels of sVCAM and TSP-2 measured in a biological fluid sample separated from a subject and (ii) the age of the subject; - calculating SC from these measured levels and age using a mathematical function as described above; - comparing the score SC with a score SB obtained by combining the previously measured levels of sVCAM and TSP-2 and age in the same subject using the same mathematical function; and - assigning the subject as follows: having progression of liver fibrosis if the score SC is higher than SB; having regression of liver fibrosis if the score SC is lower than SB; or having stable liver fibrosis if there is no significant change between SC and SB. Claim 21 A computer program comprising instructions that, when executed by a processor / processing means, cause the processor / processing means to perform the following: - (i) levels of sVCAM and TSP-2 measured in a biological fluid sample isolated from a subject suffering from progressive liver fibrosis, wherein the subject was administered an antifibrotic agent prior to the isolation of the biological fluid sample, and (ii) the age of the subject; - calculating an SE score from these measured levels and age using a mathematical function as described above; - comparing the score SC with a score SD obtained by combining the previously measured levels of sVCAM and TSP-2 and the age in the same mathematical function prior to the administration of an antifibrotic agent to the same subject; and - assigning the subject as follows: if the score SE is higher than SD, a subject not responding to treatment with an antifibrotic agent; if the score SE is lower than SD, a subject responding to treatment with an antifibrotic agent; or if there is no significant change between SE and SD, a subject having stable liver fibrosis. Claim 22 A computer assistance program comprising instructions that, when executed by a processor / processing means, cause the processor / processing means to perform the following: - (i) levels of sVCAM and TSP-2 measured in a biological fluid sample of a subject with biopsy-proven stage 1, 2, or 3 liver fibrosis; and (ii) receiving the age of the subject; - calculating an SF score from these measured levels through a mathematical function; - comparing the score SF with a predetermined cutoff value for the score SF; and - assigning the subject as follows: if the SF score is higher than the cutoff value, the subject will have liver fibrosis progress; if the SF score is lower than the cutoff value, the subject will have liver fibrosis regression; if the SF score is neither higher nor lower than the cutoff value, the subject will have liver fibrosis stable. Claim 23 A computer-assisted program in which, in any one of claims 19 through 22, the score is calculated through a mathematical function defined in claims 2, 8, 11 and 17. Claim 24 A data processing device comprising means for performing the method of any one of claims 1 to 13 and claims 16 to 18. Claim 25 A computer program product comprising instructions that cause the computer to perform the method of any one of claims 1 to 13 and claims 16 to 18 when the program is executed by the computer. Claim 26 A computer-readable storage medium comprising instructions that cause the computer to perform the method of any one of claims 1 through 13 and claims 16 through 18 when executed by a computer.
